APR 2 9 2003

1644 3005el CASE DM6909 DIV1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United . States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Keith R. Lange

Type or print name

huro

April 24, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

ARNER ET AL.

Examiner: Nolan, Patrick J.

APPLICATION NO: 09/634,287

RECEIVED

FILED: AUGUST 9, 2000

MAY 0 2 2003

FOR: AGGRECAN DEGRADING METALLO PROTEASES

TECH CENTER 1600/2900

USPTO Box Sequence P.O. Box 2127 Arlington, VA 22202

SUBMISSION OF SEQUENCE LISTING INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-3883

Date: April 24, 2003

Keith R. Lange

Attorney for Applicants

Reg. No. 44,201

CASE DM6909 DIV1 CERTIFICATE OF MAILING Libereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231. Keith R. Lange Type or print name CASE DM6909 DIV1 CERTIFICATE OF MAILING Libereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United states and in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231. Keith R. Lange Type or print name Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

RECEIVED

ARNER ET AL.

Examiner: Nolan, Patrick J.

MAY 0 2 2003

APPLICATION NO: 09/634,287

FILED: AUGUST 9, 2000

TECH CENTER 1600/2900

FOR: AGGRECAN DEGRADING METALLO PROTEASES

USPTO Box Sequence P.O. Box 2127 Arlington, VA 22202

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

The Notice to Comply dated March 25, 2003 (a copy of which is enclosed) has a shortened statutory time set to expire on April 25, 2003.

In response, applicants now submit a corrected nucleotide and/or amino acid sequence submission, including a computer readable copy, a paper copy and a Statement Verifying Identity of Above Copies.

The Commissioner is hereby authorized to charge any fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-3883

Date: April 24, 2003

Keith R. Lange

Attorney for Applicants

Reg. No. 44,201

Palicati n.N .: 09/634,287

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The

nucleotide and/or amino acid sequence disclosure contained in this application does not ply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the wing reason(s):					
THE PARTY OF THE P	9	1 .	. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.82 attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 a 18230, May 1, 1990.	25. Applicant's nd at 55 FR	
		2.	. This application does not contain, as a separate part of the disclosure on paper cop Listing" as required by 37 C.F.R. 1.821(c).	y, a "Sequence	
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
	Y				
6. The paper copy of the "Sequence Listing" is not the same as the compute "Sequence Listing" as required by 37 C.F.R. 1.821(e).			. The paper copy of the "Sequence Listing" is not the same as the computer readable "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
	П	7.	. Other:	RECEIVED	
	ш			MAY 0 2 2003	
	Ap	pli	icant Must Provide:	ECH CENTER 1600/2900	
	ß	A	n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	92N1ER 1600/2900	
-	ď	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.			
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
	For	. d	uestions regarding compliance to these requirements, please contact	• •	
		For Rules Interpretation, call (703) 308-4216			
		For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support (SIRA)			
	ıaı		Technical Assistance703-287-0200		

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

To Purchase Patentin Software.....703-306-2600